Skip to main content
OpenTrials
Completed

NCT Number: NCT07046325

Comparison Between Dexametidomedine\Bupivacaine and Plain Bupivacaine in Superior Trunk Block for Arthroscopic Shoulder Surgeries

Comparison between dexametidomedine\\bupivacaine and plain bupivacaine in superior trunk block for arthroscopic shoulder surgeries

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ain Shams University

Cairo, Egypt, 00202

About this study

This study will be conducted to investigate the efficacy of adding dexmedetomidine in STB for postoperative analgesia in patients undergoing arthroscopic shoulder surgery.

  • Inclusion Criteria:
  • age ;20-50 years old of both genders
  • American Society of Anesthesiologists physical status I and II
  • BMI less than 30
  • Arthroscopic shoulder surgeries.
  • Exclusion Criteria:
  • Patients with ASA more than II
  • Patients with a sepsis, malignancy anywhere
  • Patient with bleeding tendencies or on anticoagulation therapy
  • Patients with pre-existing neurologic deficit or neuropathy affecting brachial plexus
  • Allergy to study drugs.

Study groups:

The patients will be randomized into 2 groups:

  • Group DB: are administered Ultrasound guided STB with bupivacaine and dexametidomedine.
  • Group B: are administered Ultrasound guided STB with bupivacaine.

Primary outcome:

Duration of analgesia of Superior trunck block.

Secondary outcome:

  • Cumulative dose of postoperative consumption of the rescue analgesia during 24h after STB
  • Durations of motor blockade (DOM)
  • Residual block related neurological symptoms
  • Hemodynamic variables
  • Dyspnea and sedation scale.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ;20-50 years old
  • Both genders
  • American Society of Anesthesiologists physical status I and II
  • BMI less than 30
  • Arthroscopic shoulder surgeries.

Exclusion criteria

  • Patients with ASA more than II
  • Patients with a sepsis, malignancy anywhere
  • Patient with bleeding tendencies or on anticoagulation therapy
  • Patients with pre-existing neurologic deficit or neuropathy affecting brachial plexus
  • Allergy to study drugs.

Treatment and study plan

dexametedomidine

Drug
  • Group DB: are administered Ultrasound guided STB with bupivacaine and dexametidomedine.

Bupivacain

Drug
  • Group B: are administered Ultrasound guided STB with bupivacaine.

Primary outcomes

  1. Duration of analgesia of Superior trunck block.

    Time frame: 24 hours

    The DOA will be defined as the time interval between STB and the first need for the rescue analgesics.

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jul 1, 2025
Registry last updated
Jul 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.